Nuvation Bio Inc Total Liabilities
Nuvation Bio Inc total liabilities. Based on the latest financial reports, Nuvation Bio Inc (NUVB) has total liabilities worth $490.64 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Nuvation Bio Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Nuvation Bio Inc (2018–2025)
Total liabilities of Nuvation Bio Inc from 2018 to 2025. This chart illustrates how Nuvation Bio Inc's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of Nuvation Bio Inc to see how much of total assets are deployed in long-term investments.
Nuvation Bio Inc Competitors by Total Liabilities
The table below lists competitors of Nuvation Bio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
B.Grimm Power Public Company Limited
BK:BGRIM
|
Thailand | ฿133.69 Billion |
|
Paradox Interactive AB (publ)
ST:PDX
|
Sweden | Skr656.64 Million |
|
Xianhe Co Ltd
SHG:603733
|
China | CN¥16.96 Billion |
|
Mullen Group Ltd.
TO:MTL
|
Canada | CA$1.43 Billion |
|
Zhejiang Expressway Co. Ltd
F:ZHJ
|
Germany | €200.36 Billion |
|
A.F.P. Provida
SN:PROVIDA
|
Chile | CL$206.75 Billion |
|
Ardent Health Partners, Inc.
NYSE:ARDT
|
USA | $3.54 Billion |
|
Shenzhen Agricultural Products Co Ltd
SHE:000061
|
China | CN¥12.91 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Nuvation Bio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Nuvation Bio Inc total assets.
Liquidity & Leverage Metrics
Nuvation Bio Inc Total Liabilities Ratios Explained
Nuvation Bio Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.93 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.66 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nuvation Bio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nuvation Bio Inc (2018–2025)
The table below shows the annual total liabilities of Nuvation Bio Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $289.11 Million | +276.25% |
| 2024-12-31 | $76.84 Million | +369.61% |
| 2023-12-31 | $16.36 Million | -4.12% |
| 2022-12-31 | $17.07 Million | -43.41% |
| 2021-12-31 | $30.15 Million | +349.52% |
| 2020-12-31 | $6.71 Million | +109.36% |
| 2019-12-31 | $3.20 Million | +255.21% |
| 2018-12-31 | $902.00K | -- |
About Nuvation Bio Inc
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the ma… Read more